This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

reputable news agency


Annual two-dose SARS-CoV-2 vaccination campaign beneficial

Annual two-dose SARS-CoV-2 vaccination campaign beneficial

Annual administration of a second dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine five months after the initial dose results in fewer hospitalizations and deaths, according to a study published in the Annals of Internal Medicine.

Chad R. Wells, Ph.D., from the Yale School of Public Health in New Haven, Connecticut, and colleagues examined the effectiveness of an annual SARS-CoV-2 vaccination campaign in an age-structured dynamic transmission model in the United States; the intervention included SARS-CoV-2 vaccination with an age-specific uptake similar to that of influenza vaccination.

The researchers found that in an annual vaccination campaign, the optimal timing between the first and second dose delivered to children younger than 2 years and adults aged 50 years and older was estimated to be five months. A second booster dose resulted in 123,869 fewer hospitalizations and 5,524 fewer deaths compared with a single-dose campaign, averting $3.63 billion in costs over one year.

"Our study shows that adopting an annual vaccination campaign with the provision of a second dose to children younger than 2 years and adults aged 50 years or older can be a suitable approach to protect individuals against SARS-CoV-2 infection and associated outcomes," the authors write.

More information: Chad R. Wells et al, Evaluation of Strategies for Transitioning to Annual SARS-CoV-2 Vaccination Campaigns in the United States, Annals of Internal Medicine (2024). DOI: 10.7326/M23-2451

Journal information: Annals of Internal Medicine

Copyright © 2024 HealthDay. All rights reserved.

Citation: Annual two-dose SARS-CoV-2 vaccination campaign beneficial (2024, March 26) retrieved 25 April 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Updated COVID-19 vaccine has effectiveness of 54 percent, according to new research


Feedback to editors